Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals

Background An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions. Results This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature. Conclusions Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF.

[1]  Marcelo Lobosco,et al.  Mathematical modeling based on ordinary differential equations: A promising approach to vaccinology , 2017, Human vaccines & immunotherapeutics.

[2]  Francesco Pappalardo,et al.  Toward computational modelling on immune system function , 2019, BMC Bioinformatics.

[3]  Uma Chaudhry,et al.  Identification of potential therapeutic targets in Neisseria gonorrhoeae by an in-silico approach. , 2020, Journal of theoretical biology.

[4]  Luiz Antonio Bastos Camacho,et al.  17DD and 17D-213/77 Yellow Fever Substrains Trigger a Balanced Cytokine Profile in Primary Vaccinated Children , 2012, PloS one.

[5]  L. Camacho,et al.  Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. , 2012, Biologicals : journal of the International Association of Biological Standardization.

[6]  Michael A. Gonzalez,et al.  From genome to vaccine: in silico predictions, ex vivo verification. , 2001, Vaccine.

[7]  Francesco Pappalardo,et al.  Computational modelling approaches to vaccinology. , 2015, Pharmacological research.

[8]  S. Tyring,et al.  Vaccine immunology , 2009, Dermatologic therapy.

[9]  Vitaly V. Ganusov,et al.  Mathematical modeling provides kinetic details of the human immune response to vaccination , 2015, Front. Cell. Infect. Microbiol..

[10]  Ashish Ranjan Sharma,et al.  Computer aided novel antigenic epitopes selection from the outer membrane protein sequences of Aeromonas hydrophila and its analyses. , 2020, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[11]  Giulia Russo,et al.  Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS) , 2019, BMC Bioinformatics.

[12]  Garima Singh,et al.  A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria , 2020, International Journal of Biological Macromolecules.

[13]  Ana Carolina Campi-Azevedo,et al.  Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis , 2019, Arthritis Research & Therapy.

[14]  Constança Britto,et al.  New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters , 2015, Human vaccines & immunotherapeutics.

[15]  Marcelo Lobosco,et al.  A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine , 2018, BMC Immunology.

[16]  Luiz Antonio Bastos Camacho,et al.  Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline , 2014, BMC Infectious Diseases.

[17]  Rodrigo Weber dos Santos,et al.  A simplified mathematical-computational model of the immune response to the yellow fever vaccine , 2017, 2017 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).

[18]  Ana Carolina Campi-Azevedo,et al.  Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. , 2011, The Journal of infectious diseases.

[19]  Luiz Antonio Bastos Camacho,et al.  Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study , 2018, Vaccine.

[20]  Ana Carolina Campi-Azevedo,et al.  Booster dose after 10 years is recommended following 17DD-YF primary vaccination , 2015, Human vaccines & immunotherapeutics.

[21]  G. Screaton,et al.  The immune response against flaviviruses , 2018, Nature Immunology.

[22]  Claire-Anne Siegrist 2 – Vaccine Immunology , 2018 .

[23]  Essam H. Ibrahim,et al.  Development of Rift Valley fever (RVF) vaccine by genetic joining of the RVF-glycoprotein Gn with the strong adjuvant subunit B of cholera toxin (CTB) and expression in bacterial system , 2018, Saudi journal of biological sciences.

[24]  Luiz Antonio Bastos Camacho,et al.  Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. , 2004, Revista de saude publica.

[25]  Guilhem Richard,et al.  Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools , 2020, Frontiers in Immunology.

[26]  M. Maurin,et al.  REVIEW ARTICLE doi: 10.1111/j.1472-8206.2008.00633.x The Hill equation: a review of its capabilities in pharmacological modelling , 2008 .

[27]  Luiz Antonio Bastos Camacho,et al.  Duration of immunity in recipients of two doses of 17DD yellow fever vaccine. , 2019, Vaccine.

[28]  Ahmed Abd El Wahed,et al.  An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes , 2020, Parasites & Vectors.

[29]  Jafar Razmara,et al.  Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. , 2020, Drug discovery today.

[30]  D. Lauffenburger,et al.  Applying computational modeling to drug discovery and development. , 2006, Drug discovery today.

[31]  Rodrigo Weber dos Santos,et al.  Quantitative Validation of a Yellow Fever Vaccine Model , 2019, BIBM.